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radiotherapy (50.2Gy/27#, 50Gy/25# or 45Gy/25#) followed 
by brachytherapy (26Gy/4# or 28Gy/4# to HRCTV). In the 
current study the original treatment plans were re-optimised, 
using Brachyvision Version 11. The aim was to escalate the 
GTV(BT) dose to 140% of the original HRCTV prescription dose 
(8.4Gy and 9.8Gy/# respectively), keeping the HRCTV 
coverage and organ at risk DVH values within the tolerance 
which had been accepted for the original clinical plans. GTV 
(BT) and HRCTV were drawn according to GEC-ESTRO 
recommendations. The relationship between the volumes can 
be defined by the following equation. HRCTV2 = HRCTV1 – 
GTV(BT) The quality of the re-optimised plans was quantified 
by using dose volume histogram parameters. 
 
Results: Table 1 shows a comparison of the original and the 
re-optimised plan parameters.In 10 out of the 14 cases 
(71.4%) more than 90% of the GTV(BT) was covered by the 
140% isodose after re-optimisation.The HRCTV1 V100% was 
reduced for the re-optimised plans by an average of 2.95% 
(range 0.7-6.01%).Average coverage of HRCTV2 with the 
prescription isodose was 94.5% for the 6Gy plans, and 81.7% 
for the 7Gy plans.In 12 out of the 14 cases (85.7%) the 
treatment time was reduced with the boost plan.  
 
Conclusion: It is possible to boost the prescription dose to 
the GTV(BT) to 140% for treatment plans with interstitial 
catheters and IU within the GTV(BT) volume. Plans without 
both interstitial catheters and IU in the GTV(BT) are most 
likely to be suboptimal. This planning study demonstrates 
that dose escalation to the GTV(BT) is feasible if clinically 
indicated, and further work into clinical application and 
outcome should be considered. 
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Purpose or Objective: Locally advanced cervical cancer 
patients with a bulky high-risk clinical target volume (HR-
CTV) get the largest benefit of dose escalation in terms of 
local control. But the expected survival benefit could be 
lessened by a higher metastatic risk. We examined the 
patterns of relapse according to the HR-CTV and to the 
ability to reach the target dose. 
 
Material and Methods: Pts treated with chemoradiation 
between 04/2007 and 02/2012 were included if they had a 
disease limited to the pelvis after an exhaustive primary 
staging (PET/CT plus primary laparoscopic para-aortic 
lymphadenectomy) and if they had received concurrent 
chemotherapy. Pts received pelvic irradiation (45 Gy) then a 
PDR brachytherapy boost +/- a pelvic sequential boost for 
PET positive pelvic lymph nodes. First sites of relapse were 
examined. 
 
Results: 109 pts were included, with median follow-up of 39 
months. Median D90 HR-CTV was 73.5 Gy in case of HR-CTV ≥ 
30 cm3 (n = 28) versus 86.4 Gy in case of HR-CTV < 30 cm3 (p 
< 0.001). Pts with a not-bulky HR-CTV (< 30 cm3) experienced 
local failure in 5/81 (6.2%), versus in 6/28 (21.4 %) in case of 
bulky HR-CTV (p =0.03), but the HR-CTV volume did not 
correlate with the risk of local failures as only events. Pts 
with a bulky HR-CTV volume had a higher risk of distant 
failures: 10/28 (35.8 %) versus 7/81 (8.6 %) in case of not-
bulky HR-CTV (p = 0.002). Local failures were seen in 3/47 
(6.4 %) for pts with a D90 HR-CTV ≥ 85 Gy and in 8/62 (12.9 
%) for pts with a D90 HR-CTV < 85 Gy, respectively (p=0.055). 
Distant failures were seen in 1/47 (2.1 %) and in 16/62 (25.8 
%), respectively (p<0.001). This higher frequency of distant 
events in pts with a D90 HR-CTV < 85 Gy remained significant 
after exclusion of local failures: 0/44 (0 %) versus 11/54 (20.4 
%), respectively (p < 0.001). 
 
Conclusion: The inability to reach the target dose seems 
correlated with a higher propensity to metastases. Strategies 
integrating the metastatic risk are mandatory for maximizing 
the benefit of dose escalation. 
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Purpose or Objective: GEC-ESTRO recommendations for IGRT 
in brachytherapy, the incorporation of MRI in the planning 
and new MRI-compatible applicators have improved our 
treatments. But, in big tumours, intrauterine applicators 
don´t seem enough in order to reach a good coverage. 
Interstitial CT-MRI Utrecht (Elekta®) applicator with plastic 
needles lets improve HR-CTV and IR-CTV coverage sparing 
organs at risk. However, a further complication using 
interstitial applicators may be gynaecological bleeding during 
the withdrawal of the applicator.  
The purpose of this study is to review perioperative toxicity 
and dosimetry in patients with cervix tumours using 
interstitial CT-MRI Utrecht applicator. 
 
Material and Methods: Retrospective review of the records 
of 122 cervical cancer patients treated in our institution from 
